DDInter1928 DDInter1763
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Verapamil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Verapamil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Verapamil {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Verapamil {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Verapamil {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Verapamil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Verapamil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Verapamil {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Verapamil {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Verapamil {u} (Compound) binds {v} (Gene) SLC22A5
SLC22A5 {u} (Gene) regulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Verapamil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Verapamil (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Temsirolimus (Compound)
Verapamil (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is downregulated by Temsirolimus (Compound)
Verapamil (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Verapamil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Verapamil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Verapamil (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Verapamil (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) regulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Temsirolimus (Compound)